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NICOTINAMIDE PHOSPHORIBOSY/TRANSFERASE INTERACTION WITH 
POLYPHENOLIC MODULATOR IN THE PRESENCE OF ATP 
ELIZABETH CAMPBELL 
ABSTRACT 
 Nicotinamide adenine dinucleotide (NAD) is critical in human physiology, the 
molecule is part of redox reactions vital to metabolism and it is a substrate for multiple 
signaling proteins in the body. During times of stress in the body, which if chronic can 
lead to lifelong illness, NAD consumption by signaling proteins is increased and NAD 
concentration can be depleted. Age related illnesses are often the result of compounding 
stresses placed on the body over time. A novel way to approach understanding age-
related illness, such as diabetes type II and neurodegenerative diseases, is through 
investigation of NAD modulation.  
The importance of NAD is exemplified by the redundancy of routes in which 
NAD is produced in vivo. The predominant pathway in humans is the salvage pathway. 
The rate-limiting enzyme of the salvage pathway and key component of this research is 
Nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is a 55 kDa homodimer. It 
contains autophosphorylation and transferase activity which leads to the recycling of 
NAD in the body. The enzyme’s reaction happens sequentially with autophosphorylation 
increasing the enzyme’s affinity for the next reactant, phosphoribosyl pyrophosphate 
(PRPP). When PRPP binds the phosphorylated enzyme the affinity for NAM increases 
and promotes the conversion of NAM to NNM.  
		 vii 
Due to the physiological importance of NAD, NAMPT has become an enzyme of 
interest in multiple fields including metabolism, oncology, and neurology.  Identification 
of NAMPT modulators would aid the understanding of NAMPT’s physiological role as 
well as NAD modulation in disease. 
Through years of research, the Almeida Lab at Rhode Island College has 
identified a small polyphenolic compound, Compound 20, which consistently enhances 
NAMPT’s activity. Compound 20 is part of the anthocyanin family. Its modulation of 
NAMPT activity has been studied through enzyme activity coupled fluorescence assays. 
To move forward with investigations of Compound 20 as an allosteric enhancer of 
NAMPT, the physical interaction between the enzyme and compound needed to be 
confirmed. 
This research aimed to confirm binding between Compound 20 and NAMPT via 
fluorescence polarization assays. Further, it examined the hypothesis that the 
autophosphorylation of NAMPT enhanced Compound 20’s binding with the enzyme. 
Analysis of fluorescence polarization values revealed Compound 20 and NAMPT bind 
with a high affinity, while there is a low binding affinity between phosphorylated 
enzyme, NAMPTPO4, and Compound 20.   
In conclusion, Compound 20’s binding to NAMPT was confirmed. Further the 
hypothesis that the phosphorylation of NAMPT increased Compound 20’s binding 
affinity for the enzyme was disproved. Alternative hypotheses were investigated, and it is 
more likely Compound 20 binds prior to the enzyme’s phosphorylation and reaction 
onset. Overall this research corroborates Compound 20 as an allosteric modulator of 
		 viii 
NAMPT. The identification of this enhancer may lead to novel insights on NAMPT’s 
physiological role, as well insights on the effects of enhanced NAD concentration in 
human diseases. 
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INTRODUCTION 	 Nicotinamide adenine dinucleotide (NAD) is universally known to be an essential 
part of human biology due to its role as a co-enzyme for redox reactions in the body. 
Additionally, NAD functions as a substrate for multiple signaling protein families. Some 
examples of these protein families include Sirtuins and poly(ADP-ribose) polymerases 
(PARP). The first family participates in gene expression while the latter has a role in 
DNA repair as well as apoptosis.1,2,3 The critical role NAD plays in these life sustaining 
processes has made NAD homeostasis an exciting area of research and a large body of 
information has come forth supporting NAD modulation as a potential therapy for a 
multitude of diseases. 
NAD is a substrate of SIRT1 and increased levels of intracellular NAD lead to 
increased SIRT1 acitivty.4 Increased SIRT1 activity is being investigated as a potential 
type II diabetes therapeutic because it has been shown in mice to lower body weight, 
improve glucose homeostasis, increase metabolic rate, and improve physical activity.5 
Although currently SIRT1 molecular activators are being investigated as a means of 
therapy, increasing NAD concentration in cells is an alternative approach.5  In regards to 
cardiac disease, NAD is a substrate of SIRT3 which is a protein highly expressed in the 
heart.6 During periods of stress in a cell, NAD is depleted and the cell is susceptible to 
damage. Cardiac hypertrophy is a response the heart has to stress that can be caused from 
multiple different pathologies including hypertension and coronary artery disease. Studies 
have found that the addition of exogenous NAD inhibits the heart’s hypertrophic response 
through activation of the SIRT3-LKB-AMPK pathway in mice.6 This inhibition would 
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lower an individual’s risk of developing congestive heart failure. Both diabetes type II and 
congestive heart failure are prevalent life altering diseases and novel therapies or 
prevention techniques would have great impact. 
 
NAD Production 
NAD is redundantly produced in vivo through both de novo synthesis and the NAD 
salvage pathway.7 The salvage pathway is essential because of the continuous consumption 
of NAD by signaling proteins, which is particularly high during periods of stress.8 
Furthermore, de novo synthesis has limitations, one being that de novo synthesis requires 
dietary intake of Tryptophan and catabolic break down to generate the NAD precursor 
quinolinic acid.9 Quinolinic acid has neurotoxic properties which have been affiliated with 
Alzheimer’s, Parkinson’s, and Huntington’s disease.10–12 Furthermore, NAD consumption 
by SIRTs and PARPs generates nicotinamide.13 Unlike de novo synthesis, upregulation of 
the salvage pathway recycles intracellular nicotinamide, which is beneficial as 
nicotinamide can have opposing affects to NAD.  In vivo experiments with yeast  revealed 
that while NAD is a substrate of SIRT2 nicotinamide was an inhibitor and led to accelerated 
aging.14,15  These factors make the salvage pathway a preferred area of study in regards to 
manipulation of NAD levels. 
The classic salvage pathway occurs in two main steps. After NAD is consumed by 
signaling proteins and is converted to Nicotinamide (NAM), NAM is then converted to 
nicotinamide mononucleotide (NMN) via nicotinamide phosphoribosyltransferase 
(NAMPT).16 NAMPT requires both ATP and phosphoribosyl pyrophosphate (PRPP) for 
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this reaction and is the rate limiting step of the pathway.17 In the second step of the pathway, 
NMN adenyltransferase (NMNAT) in the presence of ATP regenerates NAD from NMN.16  
 
 
Figure 1. NAD Salvage Pathway.  Nicotinamide adenine dinucleotide (NAD) is 
constantly consumed in the body by signaling proteins including Sirtuins and PARP and 
converted to Nicotinamine (NAM). NAM in the presence of adenosine triphosphate 
(ATP) and phosphoribosyl pyrophosphate (PRPP) is converted in the rate limiting step to 
nicotinamide mononucleotide (NMN) by Nicotinamide Phosphoribosyltransferase 
(NAMPT). In the last step Nicotinamide mononucleotide adenyltransferase (NMNAT) 
uses NMN and ATP to regenerate NAD. 
 
 
NAMPT Structure and Function 
The human NAMPT gene was first isolated from peripheral blood lymphocytes 
and it was found to encode a 52 kDa cytokine.18 The cytokine functioned as a growth 
factor for B cells and the enzyme was initially known as Pre-B Cell Colony Enhancing 
Factor-1 (PBEF-1).19 Further investigations hypothesized that NAMPT had insulin like 
behavior and the enzyme was additionally named Visfatin.20 Currently, the official name 
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for the enzyme is NAMPT and it has a plethora of hypothesized roles in human 
physiology. It has become an enzyme of interest for multiple different fields including 
metabolism, immunology, and oncology.  Much of the interest in NAMPT comes from its 
critical role in NAD production as it is the rate limiting enzyme of the salvage pathway.4 
By gaining a deeper understanding of NAMPT, and identifying enzyme inhibitors and 
enhancers, the possibility of fine-tuning NAD concentration is foreseeable.  
NAMPT is a homodimer, with two 55 kDa subunits each made up of 491 
residues.19 Each subunit houses an active site that lies at the dimer interface and the 
enzyme requires dimerization for the complete formation of its active sites and catalytic 
activity.19,21  The dimer interface has roughly equal distribution of hydrophobic and polar 
residues, as well as numerous salt bridges, hydrogen bonds, and van der Waals 
interactions. 19,22 Both active sites are located at the entrance of a tunnel and contributed 
to by both monomers.22 One monomer contributes residues from five b strands and seven 
a helices, the other monomer provides a tyrosine residue and two lysine residues.22 This 
formation of the active site is believed to isolate  it from solvent.23  
NAMPT synthesizes NMN from NAM via ATPase and phosphotransferase 
activity. The enzyme’s activation is dependent on autophosphorylation of an active site 
histidine (H247).24  At physiological concentrations of ATP about 80% of NAMPT is 
phosphorylated.24  For auto-phosphorylation to occur ATP must bind with NAMPT. The 
current understanding of the binding interaction is that the adenine ring of ATP 
experiences a p-stacking interaction with one monomer’s F193 and R311.22 On the same 
monomer the ribosyl group of ATP forms hydrogen bonds with the backbone carbonyl 
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groups of G353 and F193.22 The negative charge of ATP is stabilized by cationic residues 
(R391, R40, K400) on the opposite monomer, this binding orientation allows the g-
phosphate to phosphorylate H247.22  
The conversion of NAM to NMN is believed to undergo an SN2 reaction in which 
NAM is between the aromatic rings of F193 and Y18 on opposite monomers as seen in 
Figure 2a. Additionally NAM is stabilized by its N7 and O7 atoms forming hydrogen 
bonds with D219 and R311 on the same monomer as F193.25 This places NAM in a 
position where its N1 nitrogen can attack PRPP’s C1 atom and ultimately force the 
pyrophosphate group to leave and the formation of NMN.25 Enzymes with similar 
reactions to NAMPT typically undergo SN1 reactions, but due to the lack of support for 
carbocation formation  seen in the human NAMPT reaction, it is unlikely a SN1 reaction 
occurs.25 Although phosphorylation is not required for NMN synthesis, significantly less 
energy is used for the conversion of NAM to NMN with phosphorylated NAMPT.22  
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Figure 2. Chemical Reaction and Structures Involved in NMN Synthesis.26,27,28 Figure 
2a. The stabilization of NAM with opposite NAMPT monomers is shown (monomer 
identity denoted by A/B). NAM is between the aromatic rings of F193 and Y18 of 
opposite monomers. The N7 and O7 atoms of NAM hydrogen bond with D219 and R311. 
PRPP’s bonding with NAMPT monomers shown. The pyrophosphate group is stabilized 
with cationic R392 while the 5’phosphate group is stabilized with hydrogen bonding 
through the backbone carbonyl oxygen of G384. In proposed SN2 mechanism the C1 
carbon on PRPP is attacked by N1 of NAM which promotes the pyrophosphate of PRPP 
to leave and NMN to form. Figure 2b. Shows products of reaction NMN and PPi. (Images 
taken from Wikimedia Commons)  
 
 
FK866 has been identified as an inhibitor of NAMPT. Its ability to reduce NAD 
production in cells with high metabolic rates induces apoptosis and is being investigated 
as a potential cancer therapy.28,29  Similar to FK866’s modulation of NAMPT as a 
potential therapeutic, a molecule capable of enhancing NAMPT’s activity could provide 
pharmacological uses, and possibly for an wider range of diseases. For example, 
increased NAMPT activity, and thus increased NAD production, has been proposed to 
combat neurodegenerative diseases like Alzheimer’s and dementia.30 Even more 
impressively, it has been hypothesized to slow the aging process.31 In regards to  
neurodegenerative diseases, studies have suggested that the upregulation of NAMPT is 
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protective against axonal degeneration.30 The anti-aging properties were investigated by  
a study which has shown that while decreased NAMPT activity can cause premature 
senescence in human smooth muscle cells, reintroducing NAMPT activity to an aging 
cell extended the human cell’s life.31  
Furthermore, many investigations on NAMPT’s role in metabolism have been 
conducted and although the results are still controversial, there is evidence that 
modulation of NAMPT could provide a possible therapeutic for metabolic diseases. The 
more controversial studies conclude that NAMPT itself exhibits insulin like behavior and 
promotes glucose uptake, these studies have come under questions due to lack of 
reproducible results.33,32 An alternative view on NAMPT’s role in metabolism 
hypothesizes that increased NAD biosynthesis through upregulation of NAMPT plays a 
role in glucose homeostasis. This claim is supported by findings that reveal administering 
FK866 inhibits glucose stimulated insulin secretion in pancreatic islets.32 In comparison, 
administering NAMPT’s product, NMN, to FK866 treated pancreatic islets restores 
glucose stimulated insulin secretion.32 These findings exemplify that a deeper 
understanding of NAMPT’s role in human physiology, as well as  NAMPT modulating 
compounds, may help produce novel ways to combat some of the world’s most prevalent 
diseases. 
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Figure 3. Dimeric structure of Nicotinamide Phosphoribosyltransferase 
(NAMPT)33. Enzyme contains two active sites which are primarily housed in opposite 
monomers. Dimerization is required for complete formation of active sites and catalytic 
activity of enzyme. Each subunit is 55 kDa.19  (Figure taken from Wikimedia Commons) 
 
 
 
Previous Research 
 
The Almeida lab at Rhode Island College has been researching NAMPT for years 
and has identified an allosteric modulator. Analysis began with the screening of 
NAMPT’s crystal structure which revealed a crevice that could support a small molecule 
binding.  The lab screened compounds from the National Cancer Institute Developmental 
Therapeutics Program (DTP) Diversity Set 3 data base using Autodock Vina Freeware 
and identified compounds which would interact with NAMPT based on low binding 
energies.  To eliminate sticky molecules, compounds which bound to three or more sites 
on the enzyme were eliminated. The remaining compounds were ranked based on their 
binding energies, and were screened for a modulation of NAMPT via an enzyme activity 
coupled fluorescence assay. 
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 In the enzyme activity coupled fluorescence assay a fluorescent NMN derivative 
was introduced to allow NAMPT’s activity to be quantified. The fluorescence tag was 
attached to the reaction product via the addition of acetophenone, KOH, and formic 
acid.34 Each compound was compared to baseline NAMPT activity as well as a negative 
control. The assay identified two compounds which consistently enhanced the production 
of NAMPT’s product, the compounds became known as Compound 2 and Compound 20.  
 
 
Figure 4. Fluorescence Assay Screening National Cancer Institute Compounds.35 Graph 
shows screening of 92 compounds. Preformed using Synergy HTX Multi-Mode Reader. 
Mean values of NAMPT activity per compound were plotted. Red circles indicate 
compounds which significantly altered NAMPT’s activity. Compound 20 and Compound 
2 have increased activity around 150%. Negative control FK866, a known inhibitor of 
NAMPT, shows percent activity at 0%. (Original Image, used with permission of Dr. 
Karen Almeida) 
 
 
Compound 20 
  Compound 20 is a small polyphenolic molecule, specifically it is a part of the 
anthocyanins family. Polyphenols occur naturally in food plants and contain antioxidant, 
anti-carcinogenic, and anti-inflammatory properties.36 Anthocyanins are glycosides of 
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polyhydrody-2-phelybenzopyrilium or flavylium salts. These compounds are natural 
pigments and are frequently found in vegetables and fruits.37  
Anthocyanins have been linked to health benefits, one example being improved 
cardiovascular health. Studies have found that increased anthocyanin intake is inversely 
related to risk of developing cardiovascular disease.38 While previously believed that 
anthocyanins health benefits were associated with their direct antioxidant properties, 
several studies recently found supporting evidence that  anthocyanins decrease expression 
of genes coding for enzymes involved in processes such as inflammation, monocyte 
adhesion, and transendothelial migration, all of which have a role in the development of 
atherosclerosis.38  Furthermore, anthocyanins have shown protective effects against the 
highly prevalent metabolic disease syndrome which is the combination of diabetes, high 
blood pressure, and obesity.39 Anthocyanins protect against metabolic disease syndrome 
in multiple ways, two examples include: decreasing expression of enzymes responsible 
for fatty acid synthesis and decreasing the pancreas’ glucose intolerance by protecting 
pancreatic b-cells from glucose induced oxidative stress.39 Anthocyanins are a well-
established beneficial molecular family and Compound 20’s relationship to NAMPT may 
aid in furthering the understanding of why the molecules are so beneficial to human 
health. 
The potential binding of Compound 20 takes place between the two active sites of 
the NAMPT homodimer. Through crystal structure analysis and projections made with 
Autodock Vina Freeware, the Almeida lab suggests Compound 20 binds NAMPT via 
T391, K389, and Q388.  
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Figure 5. Compound 20 at Predicted Allosteric Site.40 Compound 20 is shown in yellow. 
Projection shows polyphenol ring of Compound 20 interacts with both NAMPT 
monomers. Hydrogen bonding is seen with T391 on monomer A (3.4 angstrom) and 
T391 on monomer B (3.4 angstrom). (Original Image, used with permission of Dr. Karen 
Almeida) 
 
 
 
 To further investigate the hypothesized Compound 20 and NAMPT interaction, 
the Almeida Lab created three mutated proteins: T391A, K389A, and Q388A. The same 
enzyme activity coupled fluorescence assay as previously mentioned with the screening 
of the National Cancer Institute DTP compounds was performed on the mutated 
enzymes. Although this research is still ongoing, thus far results have shown an increase 
in enzyme activity of all mutated enzymes compared to WT NAMPT. The Almeida Lab 
is considering that there may be a conformational shift NAMPT undergoes when bound 
with Compound 20 that produces increased access to an active site channel. 
Overall the Almeida lab’s identification of Compound 20 and its modulating 
effect on NAMPT has prompted multiple research questions, and research on the 
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allosteric site where Compound 20 binds NAMPT has reached a point where a physical 
interaction should be confirmed. Additionally, information on when Compound 20 binds 
to NAMPT during the enzyme’s reaction may provide insights about a potential 
conformational shift occurring with Compound 20’s binding.  
From a broader view, the Almeida lab’s publication of Compound 20 as an 
allosteric modulator will allow further investigations into NAMPT’s physiological role. 
Ultimately advancing the understanding of NAMPT in human physiology and diseases. 
Furthermore, Compound 20 like FK866, has potential to be a therapeutic for detrimental 
diseases affecting humanity. Prior to research of this significance moving forward, it was 
essential that the interaction between Compound 20 and NAMPT was confirmed.   
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SPECIFIC AIMS 	
The goal of this research was to extend upon the Almeida Lab’s previous 
findings. Specifically, this research aimed to confirm a physical interaction between 
Compound 20 and NAMPT via fluorescence polarization assays. Compound 20 has a 
natural fluorescence which will be used to calculated the enzyme-ligand binding affinity.  
Additionally, a goal was to examine at which stage in NAMPT’s reaction Compound 20 
bound the enzyme. Previous assays conducted suggested that autophosphorylation was 
occurring prior to Compound 20’s binding, because of this and because with 
autophosphorylation the enzyme is in its “activated state,” it was hypothesized that 
Compound 20 binds NAMPT after the enzyme’s autophosphorylation. If a physical 
interaction is confirmed it would provide supporting evidence that Compound 20 is an 
allosteric modulator of NAMPT, as well as promote studies to begin in vitro. 														
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METHODS 
Previous research by the Almeida Lab at Rhode Island College generated an E.coli 
expression plasmid for wild-type human NAMPT from Invitrogen which incorporated a 
6X Histidine tag for purification. The plasmid was sequenced to confirm the insertion 
integrity. The plasmids generated were placed in BL21 Codon Plus cells from Stratagene.  	
1. Protein Expression	
 Human NAMPT was expressed from a modified pDEST42 vector obtained from 
Invitrogen and inserted into E. Coli BL21 Codon Plus cells from Stratagene. 10 mL 
starter culture supplemented with 100 ug/mL of Ampicillin was used to inoculated 1L.  
Cells were incubated at 37° C for three hours to reach log phase as measured on a 
SmartSpecTM Plus.  Log phase cultures were induced with 0.5 mM IPTG and shifted to 
20° C for 18-20 hours. Cells were centrifuged at 10,000 RPM for 20 minutes at 4°C and 
pellets were collected and stored in -80°C freezer. 
 
2. Protein Purification 
Purification was done using standard protocols of the Almeida Lab, that includes a 
Nickel NTA agarose affinity chromatography column followed by a size exclusion on a 
S200 gel filtration column from GE Lifesciences.  
2a. Nickel NTA Agarose Column 
Cell pellets were sonicated using a Branson Sonifier Sound Enclosure in Lysis 
buffer containing 300 mM NaCl, 50 mM Tris pH 7.9, 5% glycerol, 10 mM imidazole, 
	 15	
and supplemented with PIC and 2 mM DTT. Sonification method of 10 s on and 10 s off 
intervals for 20 minutes followed by centrifugation at 4° C and 15,000 RPM for 30 
minutes. Clarified cell lysate was applied to a Ni-NTA agarose resin using gravity and 
eluted with serial fractions of 200 mM and 350 mM imidazole. Purification was 
confirmed via an SDS PAGE and Coomassie stain. Fractions were concentrated to 1 mL 
total volume for size exclusion column injection. 
2b. Size Exclusion Purification 
 1 mL enriched protein fractions were injected onto AKTA protein purification 
system equipped with a HiPrep Sephacryl S200 HR size exclusion chromatography 
column. Column equilibrated in GFB containing 150 mM NaCl, 50 mM Tris pH 8.0, 5% 
glycerol, and supplemented with 2 mM DTT. Serial elutions were collected and 
purification confirmed with SDS Gel PAGE with Coomassie stain. Fractions were 
concentrated and evaluated for concentration on a Nanodrop 2000 using Protein A280 
analysis with molecular weight at 56.58 KDa and a e/100 of 78.73. Protein was stored in 
-80° C freezer. 
 
3. Fluorescence Polarization Assays  
A fluorescence polarization assay was designed for NAMPT and NAMPTPO4 using 
Cytation 3 Imaging Reader at Brown University Genomic Core Facility, and BrandTech 
384-Well Standard Microplates. Baseline Compound 20 fluorescence polarization reads 
were confirmed to determine optimal concentration of Compound 20, and optimal assay 
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temperature was established. Parameters set to excitation 485/20 nm and emission 528/20 
nm at 37° C. Fluorescence polarization was evaluated using Gen 5 software 
3a. Recombinant WT NAMPT Assay 
 300 uM NAMPT in 10% GFB was serially diluted on ice with 1X TBS. 3.12 uM 
Compound 20 diluted in 1X TBS was pipetted into appropriate wells on ice. Serial 
dilutions of NAMPT were then added into the wells. The final Compound 20 
concentration in the plate was 1.56 uM. The final NAMPT concentrations in the plate 
were: 18.5 nM, 37 nM, 73 nM, 146 nM, 293 nM, 586 nM, 1,170 nM, 2,340 nM, 4,680 
nM, 9, 370 nM, 18,750 nM, 37,500 nM, 75,000 nM, and 150,000 nM. 
3b. Recombinant WT NAMPTPO4 assay 
Assay buffer consisted of 30 mM ATP, 120 mM MgCl2, and 1X TBS.  300 uM 
NAMPT in 10% GFB was serially diluted. 3.12 uM Compound 20 diluted in 1X TBS 
was pipetted into appropriate wells and serial dilutions of NAMPT were added on ice. 
The highest concentration of enzyme had 250 mM ATP and 2 M MgCl2 solution added to 
its well. The final concentrations of the assay plate are found in Table 1. 
Table 1. Final Concentrations in NAMPTPO4 assay 
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4. Analysis of Data 
Same analysis was performed for NAMPT assay and NAMPTPO4 assay. 
Fluorescence polarization calculations were converted to anisotropy via the equation: 
 
P equals fluorescence polarization and A represents anisotropy. Anisotropy will now be 
inferred when talking about fluorescence polarization (FP). Assay FP average and 
standard deviation calculated and graphed against NAMPT concentrations on a 
logarithmic scale. An ANOVA Single Factor analysis was applied using Excel on both 
assay types’ FP averages. The average FP of the NAMPT assay and NAMPTPO4 assay 
were compared via a two tailed T-test. Dissociation curves generated through 
normalizing the fluorescence polarization values and applying a best fit non-linear 
regression using a one site binding model via Prism 8 software.  Kd calculations derived 
from the curve for both NAMPT and NAMPTPO4 
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RESULTS 
1. Recombinant human NAMPT was purified via tandem affinity and size 
exclusion chromatography. 
Nickel NTA agarose affinity chromatography was used in the purification 
performed on BL21 Codon Plus cell pellets which contained a modified pDEST42 vector 
that coded for WT NAMPT with C-terminal 6X histidine tag. The cell lysate was applied 
to Ni NTA agarose resin and retained NAMPT via the 6X histidine tag.  Serial fractions 
with high imidazole concentrations were applied to column and outcompeted NAMPT’s 
histidine tag for the nickel resin, ultimately eluting NAMPT from column.  Significantly 
enriched NAMPT protein seen Elutions 1-5 and entire cell proteome visualized in cell 
lysate (CL), as seen in Figure 6.  
 
 
Figure 6. SDS PAGE Gel of Ni NTA Agarose Column.  Gel confirmed enrichment of 
NAMPT in elutions 1-5. 20 uL of each fraction run down lane. Elutions 1-5 combined 
and concentrated down in 5% GFB for further protein purification using size exclusion 
column.  
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The enriched fractions were concentrated down and injected onto a S200 Sephacryl size 
exclusion column. Column was equilibrated in 5% GFB and supplemented with DTT to 
aid in preventing protein denaturing or aggregate formation. Gel filtration 
chromatography uses a porous resin which entraps smaller particles while allowing larger 
particles to flow through, therefore resolving protein based on its molecular weight. This 
chromatography provided purification from the larger aggregates as well as smaller 
particles that remained in the nickel fractions. Protein aggregates are clearly seen in the 
smaller peak in the chromatograph in Figure 7a, while the larger peak represents targeted 
NAMPT protein. 
 
 
Figure 7. Size Exclusion Chromatography Results. 7a. Blue line represents absorption 
(mAU) and indicated quantity of protein eluting off column. First blue peak represents 
aggregates, second larger peak indicative of WT NAMPT. 7b. SDS PAGE of Size 
Exclusion Purification. Column A through F represents elutions collected off the column. 
Column G corresponds to protein ladder. 20 uL of each sample run down lane. Elutions C 
through F showed highly concentrated and purified NAMPT which were combined and 
concentrated down in 10% GFB 
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Elutions collected off the Gel Filtration column were confirmed via SDS gel PAGE stained 
with Coomassie dye, see elutions C-F in Figure 7b. Enriched protein fractions C through F 
were combined and concentrated in 10% GFB. Concentration of protein confirmed using 
protein A280 analysis with molecular weight at 56.58 KDa and a e/100 of 78.73 
Using purifications techniques previously defined by the Almeida Lab 0.85 mg of 
NAMPT was expected to be purified per gram of wet cell pellet. This purification yielded 
13 mg of NAMPT from 6.19 g of cell pellet, with a final concentration of 150 uM. 
Therefore, two times the expected amount of purified NAMPT protein was seen. 
 
2. Recombinant human NAMPT binds novel modulator at allosteric site. 
The binding of NAMPT with Compound 20 was analyzed via fluorescence 
polarization assays.  Fluorescence polarization is one of the most sensitive and commonly 
used methods for studying protein ligand interactions.41 The phenolic rings of Compound 
20 produces a natural fluorescence, which when excited emits fluorescence intensity that 
can be measured both parallel and perpendicular to the plane of exciting light.41  The 
emitted fluorescence is a property of the molecule and its degree of rotation; small 
molecules like Compound 20 will experience a high degree of tumbling and less variation 
between its parallel and perpendicular intensities, and ultimately have lower fluorescence 
polarization values.41 When a ligand binds an enzyme the tumbling speed is decreased, 
and variation between the perpendicular and parallel intensities and fluorescence 
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polarization values increase. Compound 20’s natural fluorescence was used to confirm 
and quantify the binding of Compound 20 to NAMPT. Fluorescence polarization values 
were converted to anisotropy which is typically used in biochemical and biophysical 
studies. Anisotropy is more straightforwardly related to molecular properties, although 
both fluoresce polarization and anisotropy contain the same information.42  
There were slight variations seen in baseline fluorescence polarization measurements 
between trials for both the WT NAMPT and NAMPTPO4 assays, as seen in Figure 8a. To 
ensure that significant variance was not introduced between trials of each assay, ANOVA 
Single Factor tests were conducted. The ANOVA for NAMPT trials had an F value of 
1.16 with a Fcrit of 3.24.  ANOVA conducted on NAMPTPO4  trials had an F value of 
0.128 and a Fcrit of 3.244, proving that the variations were insignificant. 
2a. Compound 20 binds to NAMPT. 
Fluorescence polarization confirmed an interaction between Compound 20 and 
non-phosphorylated NAMPT. The increased fluorescence polarization values are 
reflective of the decreased tumbling speed of the ligand-enzyme complex. In Figure 8a. 
the NAMPT and Compound 20 binding pattern resembles a biphasic curve with the first 
inflection point at approximately 300 nM. At approximately 10,000 nM the plateau ends 
and fluorescence polarization levels increase linearly, likely due to increasing protein 
aggregation at high concentrations.43  
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Figure 8. NAMPT and Compound 20 Binding Analysis. 8a. Average and standard 
deviation of fluorescence polarization values found for three NAMPT assays conducted. 
Slight variation between each assay trial seen.  8b. Dissociation Curve for NAMPT and 
Compound 20. Graph plotted on a logarithmic scale for visualization of Kd. Kd =344 nM, 
R2 = 0.97. 
 
 
 
 
2b. Addition of ATP to NAMPT abrogates Compound 20 binding. 
Purified NAMPT was converted to NAMPTPO4 via incubation of enzyme with 30 
mM ATP and 120 mM MgCl2, this converts approximately 80% of NAMPT molecules to 
the phosphorylated form.24  NAMPTPO4 with Compound 20 showed low increases in 
fluorescence polarization values until the enzyme concentration reached approximately 
10,000 nM. Figure 9a. shows both NAMPT and NAMPTPO4 fluorescence polarization 
values increased linearly at approximately a 12:1 enzyme to ligand ratio.  
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Figure 9. Analysis of NAMPTPO4 Decreased Binding with Compound 20. 9a. Average and 
standard deviation of Compound 20 fluorescence polarization values in NAMPT and 
NAMPTPO4 assays plotted against each other. Graph reveals NAMPTPO4 has decreased 
binding with ligand compared to NAMPT. Linear increase seen in fluorescence 
polarization values in both assays starting at ~10,000 nM of enzyme. 9b. Dissociation 
Curve of NAMPTPO4 and Compound 20. Reveals NAMPTPO4 high Kd value of 52,665 nM. 
R2 value of 0.92  
 
NAMPT and NAMPTPO4  fluorescence polarization values were compared and 
plotted against each other in Figure 9a, revealing that NAMPT had significantly higher 
fluorescence polarization values  at enzyme concentrations ranging from 293-9,370 nM. 
Overlapping fluorescence polarization values between NAMPT and NAMPTPO4 were 
seen between at tail end concentrations. The two tailed T-test comparing NAMPT to 
NAMPTPO4  shown in Table 2 clearly demonstrates phosphorylated NAMPT’s lack of 
binding. Overall, comparison of NAMPT and NAMPTPO4 fluorescence polarization 
assays suggested that NAMPT binds more with Compound 20 than phosphorylated 
NAMPT. 
Dissociation curves for both fluorescence polarization assays were investigated 
via a best fit non-linear regression one site binding model. Dissociation constants (Kd) 
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between Compound 20 with NAMPTPO4 and NAMPT were calculated.  A higher Kd 
value is indicative of weaker binding. NAMPT had a Kd value of 344 nM  while 
NAMPTPO4 had a Kd value of 52,665 nM,  revealing NAMPT has a higher binding 
affinity for Compound 20 and corroborating the two tailed T-test analysis.  
 
 
Table 2. Two tailed T-test on FP averages of NAMPT and NAMPTPO4.	* 
 
* P-values for two tailed T-test on average values of FP for all assay trials. Significant 
difference in FP seen at the following concentrations of NAMPT: 293 nM, 586 nM, 1170 
nM, 2340 nM, 4680 nM, 9370 nM, and 37,500. 
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DISCUSSION 
 
 The results revealed some interesting and unexpected findings. The most 
important finding being that NAMPT and Compound 20 bind. As previously mentioned, 
prior to this study the interaction between Compound 20 and NAMPT was based on 
Autodock Vina analysis. The increased fluorescence polarization seen in the NAMPT 
fluorescence polarization assay confirmed the interaction and corroborated the Almeida 
Lab’s hypothesis that Compound 20 is an allosteric modulator of NAMPT.  
In regards to both the NAMPT and NAMPTPO4 assays, ANOVA analysis found 
that the slight variations in baseline fluorescence polarization values between trials did 
not cause statistical variance. These variations of baseline reads are likely due to the 
instrument and the complex conversion of parallel and perpendicular polarized light into 
fluorescence polarization values. Therefore, average of the three independent trials was 
used for the dissociation constant analysis. 
 
Dissociation Constant Comparison 
A surprising finding of the study was the statistically significant decreased 
fluorescence polarization of NAMPTPO4 assay. This finding indicated that auto-
phosphorylated NAMPT bonded less with Compound 20 than non-phosphorylated 
NAMPT. The Kd values found support this; NAMPT assay had a lower dissociation 
constant than NAMPTPO4 assay, suggesting that non-phosphorylated NAMPT had a 
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stronger binding affinity for Compound 20 than phosphorylated NAMPT.  Biologically 
relevant dissociation constants range from picomolar to millimolar. The tightest binding 
interactions, as seen with targeted drug therapeutics, have dissociation constants ranging 
from nanomolar to picomolar.44 While the weakest binding interactions are millimolar.44 
By these standards non-phosphorylated NAMPT had moderate binding with Compound 
20, its dissociation constant was 0.344 uM. In contrast, phosphorylated NAMPT and 
Compound 20 experienced weak binding with a dissociation constant of 52.6 uM. The 
varying Kd between the phosphorylated and non-phosphorylated version of NAMPT 
indicated that the presence of ATP is somehow interfering and decreasing the enzyme-
ligand interaction. Again, this finding was surprising because it was hypothesized that 
Compound 20 would interact more with the phosphorylated version of NAMPT which is 
ready to undergo catalytic activity.   
 
Lack of Saturation in Fluorescence Polarization Assays 
The results showed neither fluorescence polarization assay reached saturation. 
Preliminary trials with assay development showed increased binding of Compound 20 at 
high concentrations of NAMPT, however no plateau could be generated.  Similar 
increases were seen in the NAMPTPO4 trials, thus suggesting that the increased 
fluorescence polarization values were more likely artifact.  
With fluorescence polarization binding experiments, it is expected that as all the 
fluorescent ligand binds the polarization reads should reach a maximum. In the NAMPT 
assay at 1,170 nM NAMPT a plateau of fluorescence polarization values started to form. 
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At this point the enzyme and Compound 20 in the solution are roughly at a one to one 
ratio. The polarization plateau remained until NAMPT concertation was approximately 
twelve times the Compound 20 concentration. At this ratio of twelve to one enzyme to 
Compound 20, both assays had fluorescence polarization reads increase in a linear 
manner. 
Enzyme aggregate formation and nonspecific binding are two possible 
explanations for the unsaturable fluorescence polarization reads. With aggregate 
formation an increased amount of scattered light will occur. This scattered light is 
polarized and causes increased fluorescence polarization reads regardless if the 
fluorescent ligand has increased binding or not.45,43  With nonspecific binding the ligand 
has a weak affinity for at least two binding locations on the enzyme. The ligand therefore 
can bind multiple sites on the enzyme and causes non-saturable fluorescence polarization 
reads.46  The fluorescence polarization reads with nonspecific binding appear linear.41  
Since there was a high degree of binding seen in the NAMPT assay, there should 
be low or no free ligand at high concentrations of NAMPT. Therefore, it is likely that 
aggregate formation is occurring with the high concentrations of enzyme. As for 
NAMPTPO4  assay, there is still free ligand as minimal binding seemed to occur between 
Compound 20 and phosphorylated NAMPT until the high ratio was reached. Therefore, 
in the NAMPTPO4 assay a definitive conclusion cannot be drawn. It is possible that the 
free ligand started binding nonspecifically to phosphorylated NAMPT, which is 
supported by the fluorescent polarization linear increase, but this is unexpected because 
the NAMPT assay had no free ligand and the exact same increase. It is even possible that 
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Compound 20 and phosphorylated NAMPT underwent the expected specific binding and 
saturation would be seen at even higher enzyme concentration. However, it is most likely 
that aggregate formation happened, and this is supported by the fact that NAMPT had the 
same increase and statistically insignificant variations in fluorescence polarization values, 
as seen in Table 2.  
Because artifact likely caused the lack of saturation seen in the fluorescence 
polarization assays, the dissociation constants of both assays were recalculated. The 
recalculation normalized the fluorescence polarization values of NAMPT ranging from 
18.5 nM to 9,370 nM. Concentration higher than 9,370 nM were where the artificial 
fluorescence polarization values began to be read and therefore were not included.  The 
new Kd value for the NAMPT assay was found to be .194 uM with an R squared value of 
0.96 (Figure 12). The Kd value for the NAMPTPO4  assay was ambiguous, likely because 
without the artificially inflated florescence polarization values, no binding was seen in 
this assay. The recalculated values without artifact support the conclusions drawn from 
the previously discussed Kd calculations that did not account for artifact. In fact, non-
phosphorylated NAMPT and Compound 20 have an even higher binding affinity than 
previously suggested, while phosphorylated NAMPT Kd could not be determined. 
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Figure 10. NAMPT No Artifact Dissociation Curve. Recalculated dissociation curve 
without artificial fluorescence polarization values which were likely due to aggregate 
formation. Kd value found to be 0.194 uM and R2 value 0.96. Graph demonstrates non-
phosphorylated NAMPT and Compound 20’s high binding affinity. 
 
 
Literature for Autophosphorylation 
Our assay design did have limitations and the discrepancy between expected and 
actual results may lie in the experimental design. One limitation in the NAMPTPO4 assay 
was maintaining a high ATP to NAMPT ratio at the varying concentrations of NAMPT. 
Our buffer had  a final concentration of 15 mM ATP and 60 mM MgCl2, at lower 
concentrations of NAMPT this was sufficient to obtain significant phosphorylation 
levels, but as concentrations increased the ATP to NAMPT ratio decreased opening the 
possibility that not all NAMPT was phosphorylated.24 Additionally, examining similar 
autophosphorylation studies revealed it may be better practice to increase the salt and 
disulfide reducing agent concentration in the assay.24  
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Maintaining a high ATP to NAMPT ratio was important for insuring 
phosphorylation occurs. The Almeida lab’s enzyme activity coupled fluorescence assay, 
which was used to identify Compound 20’s effect on NAMPT’s activity, used a final 
concentration of 4 mM ATP to 0.539 uM NAMPT. This ratio was not sustainable in the 
NAMPTPO4  assay at high concentrations of NAMPT. The reduction in the ATP to 
NAMPT concentration ratio could have affected the degree of autophosphorylation 
occurring.  
Even with assay design setbacks, NAMPT likely did undergo 
autophosphorylation at low concentrations. In a study examining NAMPT’s 
autophosphorylation, it was identified that 77% of NAMPT underwent 
autophosphorylation at a MgATP to NAMPT ratio of 54:1.24 Therefore, although the 
NAMPT to ATP ratio  was significantly lower than in the enzyme activity coupled 
fluorescence assays, the final concentrations seen in the NAMPTPO4 fluorescence 
polarization assay likely did provide sufficient phosphorylation. Additionally, the results 
suggested autophosphorylation did occur. The statistically significant difference in the 
NAMPTPO4   assay reinforce that the addition of just ATP and MgCl2 to the NAMPT 
solution caused the enzyme to undergo a change, which impeded the enzyme’s binding 
with Compound 20. 
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Active Site and Compound 20 Binding Site Proximity  
An alternative explanation for the low fluorescence polarization values seen with 
phosphorylated NAMPT could be due to the mechanism of ATP binding to NAMPT. The 
hypothesized Compound 20 binding site involves K389, Q388, and T391. When ATP 
interacts with NAMPT, the negative charge of  ATP is partially stabilized by an 
interaction with cationic R392.22 T391 is located directly adjacent to R392 and it is 
plausible that the interaction between ATP and R392 interfered or provided steric 
hindrance in Compound 20’s ability to bind NAMPT. 
 
 
 
Figure 11. Compound 20 Allosteric Site and Active Site on NAMPT.47 Visualization of 
close proximity between enzyme’s active site and hypothesized allosteric binding site. 
Yellow indicates active sites. Red indicates allosteric sites. Both allosteric and active sites 
located at dimerization plane. (Original Image, used with permission of Dr. Karen 
Almeida) 
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Conformational Changes Induced with Autophosphorylation 
Another possibility for the decreased binding seen in the NAMPTPO4 assay may 
be due to the small structural change NAMPT undergoes when phosphorylated at H247. 
This structural change allows for more efficient synthesis of NMN, which happens 
sequentially due to the overlapped binding of reactants at the active site.22   H247 is 
phosphorylated in the active site, after phosphorylation a structural change occurs which 
increases the enzymes affinity for PRPP. 22 The structural change and increased affinity 
for PRPP are important modifications because they insure the enzyme’s reaction is 
completed and prevent ADP/ATP exchange.22 The binding of phosphorylated NAMPT 
and PRPP allow for more efficient transferase activity of NAMPT and overall synthesis 
of NAM to NNM.22 
In regards to the structural change, phosphorylated H247 can form hydrogen 
bonds with two lysine residues located at the dimer interface and on the opposite 
monomer.22 The hydrogen bonds strengthen the interactions between NAMPT’s two 
monomers, which tightens the formation of its active sites and strengthens the enzyme’s 
affinity for PRPP.22 Compound 20’s binding site is also located at the dimer interface and 
tightening of the active site channel may impede Compound 20’s ability to bind NAMPT. 
Furthermore, this structural change with phosphorylation results in an unstable high 
energy intermediate with a ΔG° of hydrolysis = −9.2 kcal mol−1, suggesting that 
phosphorylated NAMPT is too unstable for Compound 20 to bind.24  
The results, as well as analysis of phosphorylated NAMPT’s structure and 
stability, suggest that Compound 20 does not bind NAMPTPO4 but could bind NAMPT 
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prior to phosphorylation. Although Compound 20 and ATP bind NAMPT at different 
locations, phosphorylation of the enzyme seems to affect Compound 20’s ability to bind, 
therefore in a sense the molecules compete. Compound 20 binding prior to ATP is  
supported by NAMPT and Compound 20’s relatively high binding affinity. An enzyme’s 
Kd value for ATP ranges from millimolar to micromolar.44  Compound 20 and NAMPT 
non phosphorylated had a Kd value in the low micromolar range,  indicating that 
Compound 20 and NAMPT could have a higher binding affinity then ATP and NAMPT. 
The high binding affinity Compound 20 has for NAMPT supports the idea that even with 
Compound 20 competing with ATP for NAMPT, as seen in the enzyme-activity coupled 
fluorescence assay, Compound 20 could bind NAMPT more intensely than ATP. To 
further support this hypothesis future studies should confirm the binding affinity of ATP 
and NAMPT. In conclusion, the results and review suggest that Compound 20’s binding 
to NAMPT is not immediately after H247’s phosphorylation and the enzyme’s 
conformational shift, but before NAMPT’s phosphorylation.  
 
Insights on Future Research 
If Compound 20 binds prior to autophosphorylation no fluorescence polarization 
binding will be seen regardless of substrate or enzyme added to the buffer. The proposed 
binding site is sitting between the opening of the two active site channels and does not 
appear to be directly related to substrate/product binding or the chemical transformation 
of NAMPT. It is clear that Compound 20 does not bind in the active site as addition of 
Compound 20 increased the productivity of the enzyme, thus it cannot compete with the 
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substrate. The results of this study suggest that autophosphorylation occurs after 
Compound 20 binds. To test this hypothesis a new buffer solution containing a systematic 
set of NAMPT substrate and co-enzymes should be investigated in a fluorescence 
polarization assay. 
ATP and PRPP have significant overlap in their interactions with amino acids at 
the enzyme’s active site. The pyrophosphate group interacts with positively charged 
residues on the loop separating b-sheet 14 and 15, one being Arg 392. This interaction 
incorporates the flexible loop into the enzyme’s active site and ultimately enhances the 
enzymes affinity for NAM.22,25  The 5’phosphate group interacts with an oxyanion hole 
that includes residues located close to Q388 and K389 of Compound 20’s proposed 
binding site.22,25 Because of the overlapping nature of the active site, it is likely that if 
ATP’s binding prevents Compound 20’s binding, PRPPs interaction will do the same. 
 
 
Figure 12. Dimeric NAMPT interaction with PRPP.48 Grey and white ribbon represent 
monomers. Blue represents PRPP.  PRPP bonded at NAMPT active sites.  Pyrophosphate 
group interacts with lysine and arginine residues on flexible loop between b sheets. 
5’phosphate group stabilized by oxyanion hole. (Original Image, used with permission of 
Dr. Karen Almeida) 
	 35	
 
Furthermore, NAM binds the phosphorylated enzyme with PRPP at the active site 
and PRPP stays in a relatively fixed position for the conversion of NAM to NMN.22  
Therefore,  because NAM binds after ATP and PRPP the binding of NAM should not 
enhance Compound 20 binding. Additionally, PRPP and NAM’s binding work to 
stabilize the phosphorylated enzyme for its transferase activity. The complex of 
phosphorylated enzyme with PRPP and NAM is more stable than the phosphoenzyme 
alone, but the overall stability of  transition state is lower than the unphosphorylated 
enzyme, 25  
Analysis of the enzyme’s reaction suggests that due to the overlap of active site 
residues used for binding as well as stability of the enzyme complex, Compound 20 binds 
prior to any reactants’ involvement. Because of the novelty of NAMPT and Compound 
20’s interaction, it was beneficial to involve the minimal number of reactants with assay 
design, but future research with PRPP and NAM in the NAMPTPO4 assay will confirm the 
hypothesis that Compound 20 binds NAMPT prior to the onset of its sequential reaction 
with autophosphorylation. The finding that Compound 20 binds NAMPT prior to 
autophosphorylation does not affect the hypothesis that the binding of Compound 20 
induces a conformational shift, allowing for greater access to the active site channel.  
Alternatively, the binding of Compound 20 may provide an alternative chemical 
mechanism by which product may be formed. Studies have shown that NAMPT’s 
reaction likely progresses through a SN2 mechanism, yet other phosphoriboslytransferase 
enzymes, such as QAPRTase, undergo a SN1 reaction.23,49 The lack of a properly located 
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negatively charged group to stabilize the carbocation intermediate formed with SN1 
reactions was hypothesized to prevent that type of reaction from occurring.25  
Compound 20’s proposed binding site is thought to be close to the active site, in 
fact phenolic groups on Compound 20 may be able to provide carbocation stabilization. It 
is possible that Compound 20’s binding enhances NAMPT’s activity through allowing an 
alternative SN1 reaction to occur. Furthermore, the presence of a phenolic system in 
another human phosphoribosyltransferase enzyme allows SN1 reactions to occur.50 Tyr 
118 in hypoxanthine-guanine phosphoribosyltransferase (HGPTR) has been shown to 
stabilize the carbocation intermediate through its conjugated ring system as well as its 
ability to hydrogen bond.50 NAMPT’s lack of a properly located tyrosine residue is 
believed to result in NAMPT’s loss of  ability to perform SN1 reactions.25 Like Tyrosine 
118, Compound 20 has both the ability to form hydrogen bonds and p-bonding 
interactions. It may be key to stabilizing the carbocation.  
Many questions still need to be answered with regards to this research. For 
example, why does the single point mutation enzyme Q388A increase NAMPT’s activity 
and does this mutation alter Compound 20 binding. Fluorescence polarization assay on 
the single point mutations will compare the degree of binding with Compound 20 to WT 
NAMPT. Overall it is a significant finding that the lack of a phenol system near the 
active site prevents the SN1 reaction from occurring. The polyphenol system of 
Compound 20 may be a ligand substitute.   
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CONCLUSION 
 
 This research confirmed Compound 20 and NAMPT’s binding interaction.  
Further, it disproved the previous hypothesis that Compound 20 binds immediately after 
the enzyme’s autophosphorylation.  Instead this research found, that Compound 20 likely 
interacts with NAMPT prior to the onset of the enzyme’s reaction. Additionally, analysis 
of the literature suggested that Compound 20 may introduce another potential reaction 
mechanism for NAMPT. 
  To draw a more solidified conclusion on when Compound 20 binds NAMPT in 
the conversion of NAM to NMN, fluorescence polarization experiments should be 
performed which incorporate PRPP and NAM. If a binding pattern similar to the 
NAMPTPO4 assay is seen, it would confirm that Compound 20 binds NAMPT prior to the 
onset of its substrate binding.  
Fluorescence polarization assays can be conducted on the single point mutation 
enzymes and Compound 20 to further investigate the potential allosteric site. Decreased 
fluorescence polarization values would confirm mutated enzymes have decreased binding 
with NAMPT.  
This confirmed allosteric interaction will promote the publication of Compound 
20 as an allosteric enhancer of NAMPT. Because there are limited NAMPT enhancers 
identified, it will provide a tool into better understanding NAMPT’s physiological role as 
well as NAD modulation. NAD modulation may provide therapeutic benefits and this 
research supports Compound 20 as a vector to explore this potential. Studies into 
NAMPT and Compound 20’s interaction in vivo should be pursued next.	 	
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